Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Afobazole alleviates streptozotocin-induced diabetic nephropathy in rats via hypoglycemic, antioxidant, anti-inflammatory, and anti-apoptotic properties: Role of the S1R/Nrf2 antioxidant axis.
Life Sci
January 2025
Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.
Aims: Sigma-1 receptor (S1R) activation was recently identified as a promising target for preventing diabetic nephropathy (DN) by mitigating hypoxia, oxidative stress, and inflammation. This study aimed to investigate the potential reno-protective effect of the S1R agonist afobazole against streptozotocin (STZ)-induced DN in rats compared to metformin.
Materials And Methods: Rats were split into six groups: the normal control group; the diabetic control group received STZ (55 mg/kg i.
Saracatinib, a Src kinase inhibitor, enhances the renoprotective effect of metformin and losartan in diabetic nephropathy.
Arch Physiol Biochem
January 2025
Medical Physiology Department, Faculty of Medicine, Menoufia University, Shebin el Kom, Egypt.
Objective: This research assesses renoprotective effects of saracatinib (Src) in diabetic nephropathy (DN) and the potential underlying processes.
Materials And Methods: Rats were divided into: control, DN, DN + Met + Los, DN + Met + Src, and DN + Met + Los + Src. Rats' ABP, urinary albumin, urinary nephrin, and creatinine clearance were assessed.
Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus.
J Diabetes Metab Disord
June 2025
Department of Internal Medicine, University of Ioannina, Stavrou Niarchou Avenue, Ioannina, 45500 Greece.
Objectives: SGLT-2 inhibitors have been shown to exert cardio- and renoprotective actions. We aimed to investigate the underlying mechanisms using H-NMR based metabolomics in patients with type-2 diabetes mellitus who received dapagliflozin.
Methods: 50 patients with type 2 diabetes mellitus, inadequately controlled on metformin monotherapy (HbA1c > 7%) received dapagliflozin for 3 months and 30 matched patients received insulin degludec for 3 months.
Metformin and vitamin D combination therapy ameliorates type 2 diabetes mellitus-induced renal injury in male Wistar rats.
Naunyn Schmiedebergs Arch Pharmacol
September 2024
Department of Physiology, University of Ilorin, Ilorin, Nigeria.
Diabetic kidney disease is a major microvascular diabetes mellitus (DM) complication clinically associated with a gradual renal function decline. Although metformin is a common drug for managing DM, however, monotherapy treatment with any antidiabetic drug will necessitate dosage increment since type 2 DM (T2DM) deteriorates over time due to the increasing pancreatic β-cell dysfunction and will eventually require a combination therapy approach with another antidiabetic medication. Vitamin D is a food supplement that has been proven to have antidiabetic and reno-protective activities.
View Article and Find Full Text PDFTherapeutic potential of bark extracts from on renal fibrosis in streptozotocin-induced diabetic rats.
J Toxicol Environ Health A
December 2024
School of Pharmacy, Sungkyunkwan University, School of Pharmacy University, Suwon, Republic of Korea.
(MD) bark is commonly utilized in traditional medicine for diabetes prevention and treatment. The bark extract of MD is rich in prenyl or farnesyl flavonoids and stilbenes, which possess antioxidant properties. Although data suggest the potential therapeutic benefits of the use of MD in treating diabetic nephropathy (DN), the precise mechanisms underlying MD-initiated protective effects against DN are not well understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!